1/7 “Chondroitin Sulphate (CS) was shown to reduce early coronary events and late mortality in 60 patients with coronary heart disease. While 70% of control patients suffered a cardiac event at 1 month, and 14 died after 6 years of follow-up, only 13 (10%) of the CS-treated
/2
/2
2/7 patients presented an acute cardiac event and only 4 died” 😱
“Since then, the therapeutic use of Chondroitin Sulphate has been restricted essentially to Osteoarthritis. Indeed, no clinical trials have been designed to demonstrate the potential therapeutic use of CS to
/3
“Since then, the therapeutic use of Chondroitin Sulphate has been restricted essentially to Osteoarthritis. Indeed, no clinical trials have been designed to demonstrate the potential therapeutic use of CS to
/3
3/7 prevent cardiovascular events” (Well isn’t that just convenient ? CS would knock spots off any pharmaceutical drug, but CS is neither patentable nor profitable so let's not draw too much attention to its efficacy)
In addition to being an anti-inflammatory molecule,
/4
In addition to being an anti-inflammatory molecule,
/4
4/7 Chondrotin Sulphate also has antioxidant and lipid peroxidation inhibitory properties
Chondroitin sulphate is a glycosaminoglycan present in the extracellular matrix of blood vessels and its deficiency is associated with advanced Atherosclerosis
/5
Chondroitin sulphate is a glycosaminoglycan present in the extracellular matrix of blood vessels and its deficiency is associated with advanced Atherosclerosis
/5
5/7 Chondroitin sulphate reduces inflammation in mice with diet-induced obesity.
This study is the first to provide insight into the cellular mechanisms by which chondroitin sulphate interferes with Atherogenesis and opens new avenues in the management and prevention of
/6
This study is the first to provide insight into the cellular mechanisms by which chondroitin sulphate interferes with Atherogenesis and opens new avenues in the management and prevention of
/6
6/7 Atherosclerosis & Cardiovascular disease.
Chondroitin sulphate reduces Atherosclerotic plaques in atherosclerotic ApoE knockout mice.
Chondroitin sulphate interferes with the pro-inflammatory & Atherogenic effects of TNF-α on monocytes, macrophages and endothelial cells.
/7
Chondroitin sulphate reduces Atherosclerotic plaques in atherosclerotic ApoE knockout mice.
Chondroitin sulphate interferes with the pro-inflammatory & Atherogenic effects of TNF-α on monocytes, macrophages and endothelial cells.
/7
7/7 I think the pharmaceutical industry would prefer this information remain 'under wraps'😉
ncbi.nlm.nih.gov.
ncbi.nlm.nih.gov.
Loading suggestions...